基于多变量数据分析的细菌耐药性研究

蒋程; 郑造乾; 王小军; 黄萍<sup>*</sup>

引用本文:	蒋程,郑造乾,王小军,黄萍.基于多变量数据分析的细菌耐药性研究[J].中国现代应用药学,2014,31(11):1400-1404.
	JIANG Cheng,ZHENG Zaoqian,WANG Xiaojun,HUANG Ping.Study on the Bacterial Resistance Based on Multivariate Data Analysis[J].Chin J Mod Appl Pharm(中国现代应用药学),2014,31(11):1400-1404.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 1958次下载 1833次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
基于多变量数据分析的细菌耐药性研究
蒋程¹, 郑造乾¹, 王小军¹, 黄萍²
1.浙江省立同德医院药剂科，杭州 310012;2.浙江省肿瘤医院药剂科，杭州 310022

摘要:

目的分析革兰阴性菌耐药性变迁趋势，研究细菌耐药率(bacterial resistance rate，BRR)与抗菌药物用药频度(DDDs)的相关性，为临床合理用药提供依据。方法从医院信息系统抗菌药物监测分析模块提取住院患者2011—2013年共12个季度4种革兰阴性菌对9种抗菌药物的BRR数据和81种抗菌药物的DDDs数据。采用主成分分析对细菌耐药情况进行整体评价，建立BRR与DDDs的多元回归模型。结果大肠杆菌对亚胺培南/西司他丁的BRR上升较为显著，与亚胺培南/西司他丁和阿奇霉素的DDDs呈正相关。结论医院应进一步加强大肠杆菌对亚胺培南/西司他丁BRR的监测，加强对亚胺培南/西司他丁和阿奇霉素的管理。

关键词: 主成分分析多元回归抗菌药物细菌耐药率用药频度

DOI：

分类号:R95

基金项目:浙江省医药卫生科技计划项目(2012KYA040)；浙江省医学会临床科研资金项目(2011ZYC-A08)

Study on the Bacterial Resistance Based on Multivariate Data Analysis

JIANG Cheng¹, ZHENG Zaoqian¹, WANG Xiaojun¹, HUANG Ping²

1.Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China;2.Department of Pharmacy, Zhejiang Tumor Hospital, Hangzhou 310022, China

Abstract:

OBJECTIVE To provide information for the rational use of antibacterials, the variation of gram-negative bacterial resistance as well as the relationship between the bacterial resistance rate (BRR) and defined daily doses (DDDs) of antibiotics were investigated. METHODS The original BRR of 4 gram negative bacteria for 9 antibiotics and the DDDs of 81 antibiotics from 2011 to 2013 were collected from the antibiotics monitoring and analyzing module in the hospital information system (HIS). Principal component analysis (PCA) was carried to visualize the bacterial resistance in our hospital. Multivariate regression model, which mapped the influence of DDDs to BRR, was established. RESULTS The BRR of Escherichia coli for imipenem/cilastatin showed the most significant upward trend, which was positively correlated with the DDDs of imipenem/cilastatin and azithromycin. CONCLUSION This case study demonstrates that the monitoring of the BRR of Escherichia coli for imipenem/cilastatin should be strengthened by hospital. The management of imipenem/cilastatin and azithromycin should also be further strengthened.

Key words: principal component analysis multivariate regression antibiotics bacterial resistance rate defined daily doses